Psychedelics Today – Details, episodes & analysis

In this episode, Joe Moore sits down with Dr. Jason Konner, a longtime oncologist who recently left his full-time clinical role at Memorial Sloan Kettering to devote himself to the emerging intersection of cancer care and psychedelics.

Dr Konner shares how, after more than two decades treating people, he hit a wall. The accumulated grief, constant exposure to death, and intensity of oncology left him deeply burned out, though he didn't have that language for it at the time. A chance moment in a yoga class, overhearing someone say "ayahuasca retreat" just before he was scheduled for hernia surgery, became the turning point. Within a week, he was in the jungle.

That first week with ayahuasca, followed later by work with mushrooms, "absolutely transformed" his life. His fear of death lifted. The burnout he hadn't even recognized in himself was both revealed and relieved. When he returned to his practice, Konner describes feeling like he suddenly had a "superpower": he could stay present, connected, and compassionate with patients facing advanced disease without collapsing under the emotional weight.

He and Joe explore what this third path looks like: not the classic binary between either hardening and distancing as self-protection, or staying open-hearted and getting shattered. Instead, psychedelics helped him hold deep relationship with patients and families while maintaining inner stability and meaning. This opened space for authentic conversations about spirituality, fear, grief, and what it means to live with (or die from) cancer.

From there, Dr Konner zooms out to critique the broader oncology system:

• The lack of training and support for oncologists around their own emotional and existential load,
• How little space there is for relational work even though it's central to healing,
• Why many support groups and standard psychiatric approaches (like reflexively prescribing SSRIs) often miss the mark for people dealing with cancer,
• How caregivers, partners, family members, and others are deeply affected but rarely truly supported.

Joe and Jason then dig into psychedelics and oncology as a frontier: easing existential distress in patients with terminal cancer, the neglected suffering of caregivers, the potential role of psychedelics in helping people relate differently to death, and what it might mean for ICU use, aggressive end-of-life interventions, and overall healthcare costs if more people could make decisions from a place of peace rather than terror.

Dr Konner also shares a striking ovarian cancer case that hinted at powerful immune changes after shamanic work, and why he believes we need new research paradigms that can honor the integrity of retreat and ceremonial settings while still learning from them.

Finally, he talks about his early-stage project, Psychedelic Oncology, and his hope that the first wave of change starts with clinicians themselves becoming more psychedelic-literate—and, where appropriate, doing their own inner work—so better options can eventually reach the people who need them most.

Learn more - https://psychedeliconcology.com/

Clinical psychologist Dr. Genesee Herzberg joins Kyle to reflect on two decades in trauma work and 15 years inside the psychedelic ecosystem—from early MAPS conferences to running Sage Integrative Health. She traces how personal psychedelic experiences set her on a path of service, research at CIIS on MDMA-assisted therapy, and hands-on roles with MAPS: Zendo Project harm reduction, adherence rating, and ultimately serving as an MDMA therapist in clinical trials. Today she leads Sage, an integrative clinic (psychotherapy, psychiatry, bodywork, acupuncture, and functional nutrition) focused on ketamine-assisted therapy while preparing for MDMA's eventual approval. She also co-founded a sliding-scale KAP nonprofit (now Alchemy Community Therapy Center), co-edited Integral Psychedelic Therapy, and is helping to launch the International Alliance of MDMA Practitioners.

• From counterculture to mainstream: What's been gained—and lost—as psychedelics scaled.
• Accessibility vs. corporatization: Why cutting corners (prep/integration, therapeutic time) undermines outcomes and safety.
• "Myth of the magic pill": Psychedelics can catalyze change, but healing is an ongoing process anchored by integration.
• What good care looks like: Preparation → medicine sessions → robust integration, individualized cadence, and adding bodywork and functional medicine to address gut-brain links, mineral status, sleep, and somatic tension.
• Ketamine realities: Differences between psycholytic (talk-forward) and psychedelic (eyes-closed, inner-directed) dosing; why some need multiple sessions to build relationship with the medicine; risks of mail-order models (high dosing, poor screening/support), daily prescribing, addiction potential, cystitis, and safety concerns.
• Sitting, not guiding: The therapist's task is to follow the client's process; intervene sparingly and with consent—especially in trauma work where attuned co-regulation is essential.
• Multiple access pathways: Support for regulated clinical care and community, peer, and ceremonial models—paired with education and harm reduction (Zendo's SIT peer training and new crisis-responder training).
• The MDMA pause: Initial devastation at the FDA decision gave way to seeing benefits: time to strengthen ethics, accountability, training standards, and to temper hype-driven investment.
• Pace and ethics: Lessons from burnout; moving at the speed of trust; exploring "psychedelic business models" (stakeholder focus, distributed decision-making, employee ownership, public benefit structures).

• Sage Integrative Health
• Alchemy Community Therapy Center (sliding-scale KAP)
• International Alliance of MDMA Practitioners
• Integral Psychedelic Therapy (edited by Genesee Herzberg, Jason Butler, Richard Miller)

Takeaway: Thoughtful preparation, right-sized dosing, and committed integration—held within ethical, community-minded systems—turn powerful experiences into durable change.

Joe and Kyle debrief a hometown Dreamshadow Transpersonal Breathwork weekend in Breckenridge, then sketch the next chapter for Psychedelics Today: a community-centric model (Navigators) that bundles education, live streams, book and film clubs, and small-group access. They kick around the big "creativity + psychedelics" question, contrast subjective "I feel creative" with objective task performance, and highlight new research—from DMT's potential in stroke recovery to breathwork's measurable effects. They wrap with quick hits on MAPS leadership, state policy moves, and what's coming up at PT this fall.

• Breathwork > substance? A reminder that profound states are accessible without drugs; benefits of facilitating at home (rested facilitators = safer, better containers).

• What is "shamanism," really? A functional frame: non-ordinary states, interaction with the unseen, and service (healing/divination).

• Community > one-off courses: PT is shifting toward a monthly membership model to keep prices accessible, deepen relationships, and sustain more free content.

• Creativity debate: Double-blind study (DMT + harmine vs harmine vs placebo) suggests impaired convergent thinking despite increased felt creativity; how to define and measure "creativity" fairly, and other research outcomes might tell a different story.

• Whitehead & novelty: A quick tour through Alfred North Whitehead's notion of "creativity" as the principle of novelty—useful language for mapping psychedelic insight to real-world change.

• Neuro + clinical frontiers:

  • DMT for stroke (animal models): BBB stabilization and reduced neuroinflammation signal a promising adjunct to current care.

  • Cluster headaches: Emerging reports on short-acting DMT for rapidly aborting cluster cycles; more data coming soon.

  • Breathwork science: New imaging work associates music-supported hyperventilatory breathwork with blissful affect and shifts in blood flow.

• MAPS leadership: Betty Aldworth & Ismail (Izzy) Ali named permanent Co-Executive Directors.

• Policy snapshots: Colorado Natural Medicine Board recommending ibogaine (with Nagoya-compliance requirement); Alaska signature gathering; Massachusetts activity.

• Media & scene: Hamilton's recent appearances; contamination concerns in some "psilocybin" products; "psychedelics tick far more neurons than expected" paper; mixed findings for postpartum depression.

In this episode, Chris Koddermann interviews two members of the Center for the Neuroscience of Psychedelics at Mass General Hospital: founding director, author, and co-founder of three drug development companies, Dr. Jerry Rosenbaum; and psychiatrist and associate director and director of cognitive neuroscience, Sharmin Ghaznavi, MD, Ph.D.

Rosenbaum and Ghaznavi bonded over an interest in rumination, and wondered: How could the plasticity-inducing effects of psychedelics change these negative loops people find themselves in? How important is the ability to break out of those loops – and learn new patterns – when our concept of self is so central to who we are? Ghaznavi is studying the effects of psilocybin on rumination and scanning patients at multiple times throughout the process to track data we still don't really have: how psychedelic-induced neuroplasticity changes over time, and why.

They discuss:

• How much of a role the default mode network takes in the therapeutic benefits of psychedelics: Is it overblown?
• Hyperscanning, which involves scanning two individuals at the same time, looking for potential concordance in signal and/or an increased alliance between the therapist and patient
• The Schultes Legacy Project and the work of Stephen Haggarty to explore the potential of largely unstudied psychoactive plants
• Critiques of the recent ruling on Lykos and MDMA-assisted therapy and the clash between the FDA and the advisory committee: Were they really on the same page?
• The false dichotomy of neuroscience vs. patient experience: Does the subjective experience actually increase plasticity and other measurable benefits?

and more!

For links, head to the show notes page.

In this episode of Vital Psychedelic Conversations, David interviews Tiffany Hurd: microdosing coach, speaker, business leadership advisor, and student in our current cohort of Vital.

After 15 years in the corporate healthcare industry and several years on antidepressants, she started microdosing psilocybin and saw an immediate change in her life, tapering off antidepressants within a few months. She realized that she could blend her background in business development and strategy with microdosing, helping companies (and specifically company leadership) become more vulnerable, heart-centered, and innovative. She has found that the changes in people have (not surprisingly) led to improved employee mental health, better team relationships, and more open-mindedness and authenticity, and likely, a large reason for that is not the microdosing itself, but the increased attention to preparation and integration – two huge factors often not discussed with microdosing.

She talks about:

• Why mentorship/coaching has not been seen as an integral part of a microdosing practice, and why it should be
• Her drive to normalize the use of low-dose psychedelics, especially in our Western 'go all in' culture
• The benefits of pairing microdosing with other healing modalities, and how microdosing can help you embrace more of them
• Why she signed up for vital and how she feels about the course half way through
• How she deals with the illegality of substances in the corporate world

and more!

Microdosing is one of the new specialization tracks featured in our next cohort of Vital, beginning September 16. If you want to know more, send us an email or attend one of the next Vital Q+As!

For links, head to the show notes page.

The path of the psychedelic renaissance has largely touched on the aspects of therapy, personal growth, and initiation rites, but now, the relationship between psychedelics and creativity is being studied more and more. Can psychedelics really increase intellect, novelty, and problem solving?

In this episode, Joe interviews Dr. Bruce Damer: astrobiologist with a long history of work at NASA, and now the president and co-founder of the Center for MINDS, a new nonprofit researching the best ways to improve creativity and problem solving.

He talks about how we're losing our best creative minds to hyper-specialization, and while there is lots of research pointing to psychedelics as creativity-enhancers, we need to develop frameworks and protocols to be able to measure exactly how that works, and the best ways to encourage better results. The Center for MINDS is sponsoring research while running its own three year project studying creativity in a naturalistic setting, and aims to answer: How do we unlock more genius? What's the main driver for novel thinking?

He discusses:

• His path to psychedelics, including his time with 'endo-tripping': training his mind to trip without any external substances
• The importance of adding 'set up' to set and setting, representing one's intentions and preparatory work up until that point
• The tale of his extraordinary ayahuasca experience where he journeyed together with Mama Ayahuasca all the way to the beginning of life on earth
• His theory on the real origin of life, and why the 'survival of the fittest' framework shouldn't be our North Star
• The absolute necessity of mentorship from elders

and more!

The steps the Center for MINDS will take in studying psychedelics and creativity will largely be steered by people's personal stories, so please share yours with them by filling out their survey. What has worked for you? What is your personal protocol?

For links, head to the show notes page. 

Jungian psychology takes a fascinating look at the relationship between the conscious and unconscious parts of our minds. How is this framework brought more to the forefront through psychedelics and an understanding of our many parts?

In this episode of Vital Psychedelic Conversations, Johanna interviews Jung experts and Vital instructors: Maria Papaspyrou, psychotherapist and co-founder and director of the Institute of Psychedelic Therapy (IPT); and Dr. Ido Cohen, clinical psychologist and founder of The Integration Circle.

They talk about the experiences that helped them first understand the concept of multiple different parts making up their being, and dive into what it is about psychedelics that allows us to discover and work with these different parts: how the protector parts of our psyche work overtime to keep parts away from us, and how psychedelics can dissolve them, leading to a better understanding of ourselves. How much of our persona is based on who we feel we're supposed to be? What shadow parts are stopping us from being our true selves? And what amazing parts of ourselves have yet to be discovered?

They discuss:

• The idea of self as a unified entity: Does this concept make sense anymore?
• Risks in understanding how different parts work together, from justifying behaviors to inflating defensive structures
• The need to move away from solution-based to more process-focused frameworks, and the power in treating healing and growth as an ongoing process
• The rejection of the shadow and the archetypal (and impossible) wish to extinguish all suffering
• The large discrepancy between what people think being a psychedelic facilitator is vs. the reality

and more!

If you really want to dig into Jungian ideas, Jungian psychology is one of the new specialization tracks featured in the next cohort of Vital, beginning September 16. If you want to know more, send us an email or attend one of the next Vital Q+As.

For links, head to the show notes page. 

As many mushroom enthusiasts will attest: the more you learn about the fungal kingdom, the more you see how important mushrooms are to every ecosystem they're a part of – and how life-changing a relationship with them can be.

In this episode, Joe interviews Jasper Degenaars: mycologist, educator, and the Hyphae Headmaster at Fungi Academy, offering retreats, communal living, and online courses to teach people how to grow mushrooms and form a deeper connection with them.

Degenaars tells of his path to Guatemala and the Fungi Academy, from foraging to cultivation, to the impact psychedelic experiences have had on his life. He believes that mushrooms show up where people like to live; that they are integral to ecosystems, and that they are the masters of death and life – and of ego death and rebirth. The Fungi Academy has several several in-person events for which they just opened up registration, self-paced courses you can enroll in now, and their next Sacred Mycology Summit takes place Feb. 23 – 25, 2025.

He discusses:

• The importance in studying the entire organism rather than just specific compounds
• The stoned ape theory and possible new evidence
• Why he prefers the term 'magic mushrooms' to the reductionist way of only talking about psilocybin
• The clash between clinical Western approaches and Indigenous tradition
• The Iron law of prohibition and how MDMA has gotten stronger and stronger
• His desire to move more into permaculture, including courses teaching it alongside the fundamentals of psychedelics: How can they work in tandem?

and more!

For links, head to the show notes page. 

Psychedelics in palliative care has become an exciting new framework for people looking to ease anxiety and embrace spirituality, but the concept is not as simple as just providing a substance.

In this episode, Joe interviews Livi Joy: Director of Health and Safety, Existential Palliative Ministry Lead Facilitator, and more at Sacred Garden Community (SGC).

As she screens applicants for SGC (and Beckley Retreats), she talks a lot about the process and the safety measures that are absolutely necessary when using psychedelics in palliative care – especially under the framework of the Religious Freedom Restoration Act. Does the patient have at least one strong support person? Do they need to start or increase therapy? Does their home need to be rearranged due to possible fall risks? How will certain medications muffle their experience? Are they truly physically healthy enough to be able to handle a powerful journey? And also, is the sacrament always necessary?

She discusses:

• How preparation questions for a journey are often in line with preparation for death
• Why it's important to provide these experiences for people far from the dying process itself
• What Sacred Garden's core tenant of faith that everyone can have a direct experience of the divine in this lifetime means to her
• Atheism and the complications that arise when discussing spirituality and consciousness: Who's really in charge?
• How psychedelics can help with understanding and preparing for death, but our culture is too death-phobic too embrace it

and more!

For links, head to the show notes page: 

In this episode, Joe interviews Erica Rex, MA: award-winning journalist, past guest, thought leader on psychedelic medicine, and participant in one of the first clinical trials using psilocybin to treat cancer-related depression.

She tells the story of her recent harrowing experience, brought on by 6 times the amount of Syrian rue that was recommended: from entities threatening her, to a sense of terror she was going to die, to finding her way out of it with time, and most importantly, context to process and a strong support system. She and Joe emphasize the reality that bad trips can happen at any time, with any dose, for any reason, and that – if you can make your way through the experience without being traumatized – you can learn a lot about yourself during those states.

She discusses:

• Methods to help others having a bad experience
• Her skepticism about psychedelic therapy being in a medical context at all
• Her thoughts on the recent ICER recommendation against approving MDMA and the multiple topics not addressed
• Possible complications from MDMA use nobody talks about, from cytotoxic effects to even sudden-onset psychosis
• The pathologizing of anything outside the ordinary, to the point that we're trying to suppress natural human emotions and reactions

and more! 

Rex's book, "The Heroine's Journey: A Woman's Quest for Sanity in the Psychedelic Age" will be published by She Writes Press in the spring of 2026.

For links, head to the show notes page.